Skip to main content
Cardiolucent

Condition

Obesity

Cardiovascular-focused obesity care with modern pharmacotherapy and lifestyle support.

Obesity is a chronic, treatable condition characterized by excess body fat that meaningfully raises the risk of nearly every cardiovascular disease — hypertension, diabetes, atherosclerosis, atrial fibrillation, heart failure with preserved ejection fraction, sleep apnea, and many others. From a cardiology perspective, obesity is not a moral failing or a simple matter of willpower but a complex metabolic and neurohormonal disorder. The field has been transformed in recent years by GLP-1 receptor agonists and related medications, which produce weight loss comparable to bariatric surgery in many patients along with substantial cardiovascular benefit. Dr. Kedan treats obesity as a cardiovascular condition deserving of the same rigor as hypertension or hyperlipidemia, with personal counseling and coordination of pharmacotherapy.

What Cardiolucent Evaluates

  • Weight, waist circumference, BMI, and body composition trends
  • Blood pressure with home and ambulatory monitoring
  • Advanced lipid panel and metabolic profile including glucose and HbA1c
  • Echocardiography with POCUS to screen for structural cardiac effects
  • Sleep apnea screening
  • Cardiovascular risk assessment and imaging when indicated
  • Coordination with primary care, endocrinology, and bariatric medicine for medication and surgical options

Common Symptoms

  • Shortness of breath with exertion
  • Fatigue and reduced exercise tolerance
  • Snoring, witnessed apneas, or daytime sleepiness suggesting sleep apnea
  • Joint pain limiting activity
  • Symptoms of associated conditions: high blood pressure, diabetes, atrial fibrillation
  • Many cardiovascular consequences of obesity are silent until they manifest as events

Risk Factors

  • Family history of obesity
  • High-calorie diet rich in refined carbohydrates and ultra-processed foods
  • Sedentary lifestyle
  • Insufficient or poor-quality sleep
  • Certain medications (steroids, some antipsychotics and antidepressants)
  • Hormonal conditions such as PCOS and hypothyroidism
  • Chronic stress and shift work
  • Socioeconomic and environmental factors

How Cardiolucent Approaches Treatment

Treatment is multimodal. Sustained lifestyle change remains foundational — Mediterranean-style dietary patterns, structured aerobic and resistance exercise, sleep optimization, and stress management. Pharmacotherapy now plays a much larger role: GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce substantial weight loss and provide direct cardiovascular benefit, including in patients without diabetes. Bariatric surgery remains an effective option for selected patients. Dr. Kedan integrates these tools with cardiovascular risk-factor management and coordinates with primary care or bariatric medicine when appropriate.

Common Questions

Frequently Asked Questions

Why is obesity a cardiology problem?
Obesity drives nearly every cardiovascular disease — hypertension, diabetes, atherosclerosis, atrial fibrillation, heart failure with preserved ejection fraction, and more. Addressing obesity often unwinds multiple cardiovascular conditions at once, which is why it is increasingly a central part of cardiology care.
Are GLP-1 medications safe for the heart?
GLP-1 receptor agonists not only produce substantial weight loss but also reduce cardiovascular events in landmark trials, including in patients with obesity but without diabetes. Cardiovascular safety is among their best-established attributes. Side effects, particularly gastrointestinal, do occur and are usually manageable.
How much weight loss is enough to make a cardiovascular difference?
Even modest weight loss of 5–10% produces meaningful improvements in blood pressure, lipids, glucose, sleep apnea, and exercise tolerance. Greater weight loss generally yields greater cardiovascular benefit, which is part of why the newer medications producing 15–25% loss have been transformative.
Is exercise alone enough?
Exercise alone usually produces modest weight loss but substantial improvements in cardiovascular fitness, which independently reduces cardiovascular risk. The most effective approach combines exercise, dietary change, sleep optimization, and, when appropriate, pharmacotherapy.
What about bariatric surgery?
Bariatric surgery remains the most durable treatment for significant obesity and produces meaningful cardiovascular benefit. It is an option for selected patients, particularly those with severe obesity or significant comorbidities who have not achieved adequate response to medical therapy. Dr. Kedan helps determine when surgical evaluation is appropriate.
Why do diets fail so often?
Obesity is a complex neurohormonal disorder, and the body strongly defends its weight set point through hunger and metabolic adaptation. This biology is why willpower alone is insufficient for many patients and why effective pharmacotherapy and surgery have such impact — they alter the underlying biology rather than relying on conscious restriction.
Should I worry about heart failure with preserved ejection fraction?
HFpEF is increasingly recognized as an obesity-related condition. Weight loss can meaningfully improve symptoms and reduce events in HFpEF, and SGLT2 inhibitors and GLP-1 agonists both have demonstrated benefit. Dr. Kedan screens for HFpEF in patients with obesity and symptoms suggestive of it.
How does sleep apnea fit in?
Sleep apnea is extremely common with obesity and is itself a major cardiovascular risk factor, driving hypertension, atrial fibrillation, and heart failure. Screening and treating sleep apnea is one of the highest-yield interventions in obese patients with cardiovascular disease.
What does Cardiolucent do differently?
Dr. Kedan takes the time to engage meaningfully with obesity as a cardiovascular condition rather than a checkbox. Extended appointment lengths allow real counseling, coordination of pharmacotherapy with primary care or endocrinology, and integration with cardiovascular risk-factor management.
How do I schedule a consultation?
Call (310) 304-5555 or use the contact form to schedule with Dr. Kedan at the Beverly Hills office. Cardiolucent does not bill Medicare or insurance; a detailed superbill is provided for any out-of-network reimbursement.

Explore

Related Conditions

Cardiovascular-focused obesity care, done right.

Schedule a consultation with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.